These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 5841751)

  • 1. Biochemical correlates of behavior in schizophrenic patients. Schizophrenic patients receiving tryptophan and methionine or methionine together with a monoamine oxidase inhibitor.
    Berlet HH; Matsumoto K; Pscheidt GR; Spaide J; Bull C; Himwich HE
    Arch Gen Psychiatry; 1965 Dec; 13(6):521-31. PubMed ID: 5841751
    [No Abstract]   [Full Text] [Related]  

  • 2. Methionine and tryptophan loading in schizophrenic patients receiving a MAO inhibitor: correlation of behavioral and biochemical changes.
    Spaide J; Neveln L; Tolentino J; Himwich HE
    Biol Psychiatry; 1969 Jul; 1(3):227-33. PubMed ID: 5352654
    [No Abstract]   [Full Text] [Related]  

  • 3. Schizophrenic behavior and urinary tryptophan metabolites associated with cysteine given with and without a monoamine oxidase inhibitor (tranylcypromine).
    Spaide J; Tanimukai H; Ginther R; Bueno J; Himwich HE
    Life Sci; 1967 Mar; 6(5):551-60. PubMed ID: 4226702
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative behavioral and biochemical effects of tranylcypromine and cysteine on normal controls and schizophrenic patients.
    Narasimhachari N; Heller B; Spaide J; Haskovec L; Fujimori M; Tabushi K; Himwich HE
    Life Sci I; 1970 Sep; 9(18):1021-32. PubMed ID: 5478406
    [No Abstract]   [Full Text] [Related]  

  • 5. [Disturbances of tryptophan metabolism during methionine and nialamide administration in chronic schizophrenic patients].
    Rosengarten H; Stencka K; Kowalska K; Wardaszko-Lyskowska H; Szemis A; Wlosińska I; Krzyzowski J; Jus A
    Psychiatr Pol; 1970; 4(3):261-8. PubMed ID: 5459695
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma amino acids in schizophrenic patients with methionine or cysteine loading and a monoamine oxidase inhibitor.
    Spaide JK; Davis JM; Himwich HE
    Am J Clin Nutr; 1971 Sep; 24(9):1053-9. PubMed ID: 5094479
    [No Abstract]   [Full Text] [Related]  

  • 7. Detection of psychotomimetic N,N-dimethylated indoleamines in the urine of four schizophrenic patients.
    Tanimukai H; Ginther R; Spaide J; Bueno JR; Himwich HE
    Br J Psychiatry; 1970 Oct; 117(539):421-30. PubMed ID: 5312352
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of tryptaminergic mechanisms in the elements of the behavioural syndrome evoked by tryptophan and a monoamine oxidase inhibitor [proceedings].
    Crow TJ; Deakin JF
    Br J Pharmacol; 1977 Mar; 59(3):461P. PubMed ID: 843707
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of tryptamine in the behavioural changes caused by a monoamine oxidase inhibitor and L-tryptophan [proceedings].
    Curzon G; Marsden CA
    Br J Pharmacol; 1977 Jun; 60(2):307P-308P. PubMed ID: 880472
    [No Abstract]   [Full Text] [Related]  

  • 10. Individual steroid hormones in schizophrenic males.
    Varma VK; Amma MK; Ghosh A
    Indian J Med Res; 1978 Mar; 67():443-52. PubMed ID: 689720
    [No Abstract]   [Full Text] [Related]  

  • 11. URINARY INDOLES IN SCHIZOPHRENIC AND PSYCHONEUROTIC PATIENTS AFTER ADMINISTRATION OF TRANYLCYPROMINE (PARNATE) AND METHIONINE OR TRYPTOPHAN.
    SPRINCE H; PARKER CM; JAMESON D; ALEXANDER F
    J Nerv Ment Dis; 1963 Sep; 137():246-51. PubMed ID: 14051939
    [No Abstract]   [Full Text] [Related]  

  • 12. L-METHIONINE AND L-TRYPTOPHAN FEEDINGS IN NON-PSYCHOTIC AND SCHIZOPHRENIC PATIENTS WITH AND WITHOUT TRANYLCYPROMINE.
    ALEXANDER F; CURTIS GC; SPRINCE H; CROSLEY AP
    J Nerv Ment Dis; 1963 Aug; 137():135-42. PubMed ID: 14047820
    [No Abstract]   [Full Text] [Related]  

  • 13. URINARY TRYPTAMINE AND INDOLE-3-ACETIC ACID EXCRETION BY SCHIZOPHRENIC PATIENTS: USE OF THE TRYPTAMINE/INDOLE ACETIC ACID RATIO AS AN INDEX OF MONOAMINE OXIDASE INHIBITION.
    LABROSSE EH; KOPIN IJ; FELIX WR; WESTLAKE RJ
    J Psychiatr Res; 1964 Oct; 2():185-97. PubMed ID: 14242376
    [No Abstract]   [Full Text] [Related]  

  • 14. [Excretion of 17-ketosteroids, 17-hydroxycorticosteroids, catecholamines and vanillinmandelic acid in obesity during short-term total fasting].
    Ciświcka-Sznajderman M; Januszewicz W; Sznajderman M; Wocial B
    Pol Arch Med Wewn; 1968; 40(1):21-7. PubMed ID: 5638934
    [No Abstract]   [Full Text] [Related]  

  • 15. Time studies on the effects of tranylcypromine plus tryptophan on formation of tryptamine and 5-hydroxytryptamine in rat brain.
    Hay JL; McKim HR; Baker GB; Dewhurst WG
    Proc West Pharmacol Soc; 1982; 25():133-5. PubMed ID: 7122487
    [No Abstract]   [Full Text] [Related]  

  • 16. Proceedings: The role of brain dopamine in the hyperactivity syndrome produced in rats after administration of L-tryptophan and a monoamine oxidase inhibitor.
    Grahame-Smith DG; Green AR
    Br J Pharmacol; 1974 Mar; 50(3):442P-443P. PubMed ID: 4853875
    [No Abstract]   [Full Text] [Related]  

  • 17. [Biochemical mechanism of action of nicotinic acid, nicotinamide, methionine and D-penicillamine in treatment of psychoses].
    Kanig K
    Arzneimittelforschung; 1970 Jul; 20(7):909-11. PubMed ID: 4248467
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of tranylcypromine and pargyline on brain tryptamine.
    Tabakoff B; Moses F; Philips SR; Boulton AA
    Experientia; 1977 Mar; 33(3):380-1. PubMed ID: 870336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical aspects of schizophrenia.
    Lewis ME
    Essays Neurochem Neuropharmacol; 1980; 4():1-67. PubMed ID: 6104597
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic effects of methionine in schizophrenic patients pretreated with a monoamine oxidase inhibitor.
    Kakimoto Y; Sano I; Kanazawa A; Tsujio T; Kaneko Z
    Nature; 1967 Dec; 216(5120):1110-1. PubMed ID: 6075251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.